• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

This is The Report For Professionals Interested To Grasp The Field Of Apoptopic Drug Targets In Oncology

Posted on: Tuesday, 25 March 2008, 09:01 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c86597) has announced the addition of "Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma" to their offering.

This is the report for professionals interested to grasp the field of apoptopic drug targets in oncology and at the same time have an extensive R&D overview of lung cancer and melanoma. This extensive 540+ pages report compiles and analyzes Apoptosis, the type of death about whose genetically controlled pathways we know the most, and further give an in depth analysis in two key oncology areas; Breast- and Prostate cancer

The author has surveyed apoptopic drugs in oncology and identified 119 drug targets, belonging to 114 drugs. 90 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 114 apoptopic drugs designed for the treatment of 48 different cancer indications.

To fuel the scientific and competitive thinking, the author opens the gate into the presence and relevance of protein-protein interactions between identified targets of apoptopic drugs. No less than 452 protein-protein interactions were recognized among 96 of the 119 included apoptopic drug targets.

The report by the numbers

- A hundred different tables. Includes more than 1,500 active links to related resources on the Internet

- 114 apoptopic drugs, under development by 87 investigators, are included, covering more than 430 developmental projects in cancer

- 119 Unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other apoptopic drug targets, linked cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.

- 90 Unique drug target combinations of apoptopic drugs

- 452 protein-protein interactions among apoptopic drug targets

- Extensive pathway analysis of drug targets

Contents:

1 Executive Summary

2 Methodologies

3 Table of Contents

4 Introduction to Apoptotic Drugs in Oncology

5 Apoptopic Drug Compound Types and Sub-cellular Localizations of Targets

6 The Cancer Genome Project and Apoptopic Drug Targets

7 Protein Expression Profiles of Apoptopic Drug Targets in Human

8 Pathway Analysis of Drug Targets of Apoptopic Drugs

9 Protein-Protein Interactions Between Identified Apoptopic Drug Targets

10 Available Biological Structure Data on Apoptopic Drug Targets

11 Drug Target Profiles of Apoptopic Drug Targets in Oncology

12 Apoptopic Drug Target Mix by Development Stage

13 Apoptopic Drug Target Mix by Cancer Indication

14 Apoptopic Drugs and their Targets by Companies

15 Lung cancer: An Introduction

16 Progress in Current Lung Cancer Treatment Strategies

17 Key Drug Strategies in Lung Cancer

18 Competitive Landscape in Lung Cancer Drug Development: The Late Stage Pipeline

19 Etiology and Pathophysiology of Melanoma

20 Current Melanoma Treatment Strategies

21 Key Melanoma Therapy Strategies

22 Current Melanoma Drug Development: Late Stage Pipeline

23 Current Melanoma Drug Development: Early Stage Pipeline

24 Appendix 1. Treatment Guide Lines Lung Cancer*

25 Appendix 2: Selected Company Profiles

26 Appendix 3 Progress profiles on approved drugs

27 Appendix 4: Treatment Guide Lines Melanoma

28 Disclaimer

29 Drug Index

30 Company Index

3.1 List of Tables

3.2 List of Boxes

3.3 List of Figures

Figure 1: Distribution of Compound Types Among Apoptopic Drugs

Figure 2: Primary Sub-cellular Localization of Drug Targets

For more information visit http://www.researchandmarkets.com/reports/c86597

Source: Business Wire

More News in this Category